Optimal Long-Acting Injectable Antipsychotic Management During COVID-19

J Clin Psychiatry. 2021 Jan 12;82(1):20l13730. doi: 10.4088/JCP.20l13730.

Authors

Sarah A MacLaurin^{1

2

3}, Caitlin Mulligan^{2

3}, Manjola Ujkaj Van Alphen^{2

3

4}, Oliver Freudenreich^{2

3

4}

Affiliations

¹ Freedom Trail Clinic, 25 Staniford St, Boston, MA 02114. [email protected].
² North Suffolk Mental Health Association, Boston, Massachusetts, USA.
³ Massachusetts General Hospital, Boston, Massachusetts, USA.
⁴ Harvard Medical School Boston, Massachusetts, USA.

PMID: 33434959
DOI: 10.4088/JCP.20l13730

No abstract available

MeSH terms

Adult
Antipsychotic Agents / administration & dosage*
Boston
COVID-19* / epidemiology
COVID-19* / prevention & control
Communicable Disease Control / methods*
Community Mental Health Services / methods
Community Mental Health Services / organization & administration
Delayed-Action Preparations / administration & dosage*
Delivery of Health Care / trends
Disease Transmission, Infectious / prevention & control
Female
Humans
Male
Organizational Innovation
SARS-CoV-2
Schizophrenia / drug therapy*
Secondary Prevention* / methods
Secondary Prevention* / organization & administration

Substances

Antipsychotic Agents
Delayed-Action Preparations